surmount-1 tirzepatide non-diabetic obesity trial

surmount-1 tirzepatide non-diabetic obesity trial once weekly for the treatment of in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 💊 Could a new medication

Name: surmount-1 tirzepatide non-diabetic obesity trial once weekly for the treatment of in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 💊 Could a new medication
Brand: www.cmvroncone.com
SKU: 26720078376
Price: 23.16 USD
Availability: InStock
Rating: 4.6498 (22 reviews)

SKU: 26720078376

4.6

USD23.16 USD51.16

Pay in 4 interest-free payments of $5.79 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 20 - Aug 25

Description

Based on the Wegovy and Mounjaro timelines, MHRA approval is realistic in late 2027 to mid 2028, with NICE recommendation following 6 to 18 months later